Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
JNJ-678)Rilematovir (JNJ-678)JNJ-678 (JNJ-53718678)Rilematovir, 10 mM in DMSOJNJ-53718678 (JNJ53718678GTQTUABHRCWVLL-UHFFFAOYSA-NRilematovir (Synonyms: JNJ-678GTQTUABHRCWVLL-UHFFFAOYSA-N,JNJ-53718678
JNJ-8678JNJ 53718678RSV F Protein Inhibitor JNJ-53718678RSV Fusion Protein Inhibitor JNJ-53718678Respiratory Syncytial Virus Fusion Protein Inhibitor JNJ-53718678Rilematovir [INN]3-((5-Chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-2(3H)-oneUNII-NQ99E8OH3P
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
Signal word
Warning
Symbol(GHS)
GHS07
Chemistry & industry
Applications
UsesRilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.